Solvent-induced photophysical properties and stability of clonazepam and Chlordiazepoxide Authors: Roshanak Kian, Mohammad Sadegh Zakerhamidi, Zeynab Ara Merajin Published: 2025 ABSTRACT AbstractUnderstanding how solvent environments influence the electronic behavior and molecular stability of nitrogen–based heterocyclic drugs is essential for optimizing their pharmaceutical performance in both ground and excited states. Such knowledge is vital for predicting drug stability, guiding formulation design, and determining suitable storage conditions. In this study, Clonazepam and Chlordiazepoxide—representative nitrogen–based heterocyclic drugs—were systematically investigated in fourteen solvents of varying polarity. Clonazepam exhibited a more pronounced intramolecular charge transfer (ICT), as evidenced by a greater dipole moment shift between the ground and excited states. Solvent–drug interactions were quantitatively analyzed using the Kamlet–Abboud–Taft (KAT) and Catalán models, revealing that solvent acidity and basicity predominantly govern the strength and nature of these interactions. A novel Dynamic Solvatochromic Indicator (DSI) was introduced as a complementary photophysical metric for evaluating molecular integrity and solvatochromic resilience, demonstrating that Clonazepam is more stable in hydrophobic media, whereas Chlordiazepoxide exhibits enhanced stability in polar environments. These findings underscore the critical role of solvent polarity and hydrogen–bonding capability in modulating drug behavior and provide practical insights for formulation development and solvent selection in drug delivery systems.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-30955-w.Keywords: Benzodiazepines, Dynamic solvatochromic indicator, Kamlet–Abboud–Taft model, Solvent polarity, Dipole moment, Solvent accessible surfaceSubject terms: Chemistry, Drug discovery Introduction Benzodiazepines such as Clonazepam (Klonopin and Rivotril) and Chlordiazepoxide (Librium) are widely prescribed psychoactive agents that act on the central nervous system, making them effective in the treatment of anxiety, insomnia, and seizure disorders1–8. These compounds share a nitrogen–containing heterocyclic core structure, which plays a central role in their pharmacological activity by modulating γ-aminobutyric acid type A (GABAA) receptors. The presence of nitrogen atoms facilitates strong interactions with receptor binding sites, while substituents such as halogens or nitro groups influence their electronic properties, lipophilicity, bioavailability, and therapeutic efficacy9–16. The pharmacokinetic and pharmacodynamic profiles of benzodiazepines are tightly linked to key physicochemical properties, including dipole moment, lipophilicity, protein binding affinity, and pH–dependent solubility. These features significantly influence drug absorption, membrane permeability, and metabolic stability17–19. Moreover, excited–state polarity–often enhanced by intramolecular charge transfer (ICT)–can further affect biological behavior by altering interactions with enzymes, transport proteins, and membranes. While the clinical performance of benzodiazepines has been extensively studied, the effects of solvent polarity and solute-solvent interactions on their photophysical properties and molecular stability remain underexplored. Solvent environments are known to modulate electronic structure, especially in excited states where ICT effects are prominent. Such variations are relevant in pharmaceutical formulations and biological systems, where local polarity can impact molecular reactivity and degradation pathways. Our previous research has investigated multiple drug classes, correlating their substituent-dependant behavior with solvent interactions. These efforts have focused on: (i) correlating functional group polarity with environmental interactions, (ii) characterizing solvent-induced spectral shifts, (iii) comparing spectroscopic data with theoretical models, (iv) evaluating the influence of polar versus nonpolar media, and (v) analyzing drug-biomolecule interactions including binding to DNA, proteins, and enzymes22–36. To complement conventional stability assessments such as degradation kinetics and forced degradation studies, we introduce the Dynamic Solvatochromic Indicator (DSI) as a practical metric for evaluating molecular resilience across diverse solvent environments. High DSI values indicate strong resistance to solvent–induced degradation. Given that most pharmaceutical formulations operate in solution, understanding the role of solvent parameters in modulating stability and photophysical properties is critical37. Solute-solvent interactions can be broadly categorized as specific (e.g., hydrogen bonding, donor–acceptor interactions) and non-specific (e.g., dipolar and electrostatic forces). Two empirical models, the Kamlet–Abboud–Taft (KAT) and Catalán models are widely used to quantify these effects38. The KAT model describes solvent effects using three parameters: dipolarity/polarizability (π*), solvent basicity (β) and solvent acidity (α)39–41. Alternatively, the Catalán model offers a complementary approach, characterizing solvents based on their polarity/polarizability (SPP), solvent basicity (SB) and solvent acidity (SA)42. These models are widely applied in pharmaceutical research to interpret solvent–dependant spectral changes and drug behavior. Solvent effects on the spectroscopic and photophysical behavior of molecules have long been recognized as essential in understanding their stability and reactivity. In particular, solvent parameters such as polarity/polarizability (π*), hydrogen–bond donor (α), and acceptor (β) abilities in the KAT scales, or their Catalán equivalents, significantly influence absorption and emission spectra, electronic transitions, and dipole moment variations. Several studies have demonstrated that systematic variations of solvent parameters can predict photophysical trends and rationalize solvent–solute interactions. For instance, polarity–induced fluorescence shifts and solvatochromic responses have been extensively analyzed to establish solvent–solute correlation models. Literature reports confirm these effects across a variety of systems, highlighting the importance of carefully evaluating solvent contributions43–46. These findings support the view that solvent descriptors are indispensable tools in linking molecular structure to photophysical behavior, which underpins the approach followed in the present study. In this study, we examine how solvent polarity and hydrogen–bonding capacity influence the photophysical behavior and stability of Clonazepam and Chlordiazepoxide across fourteen solvents with varying polarity profiles. Ground–and excited–state dipole moments were determined to probe ICT behavior, while solvent–drug interactions were analyzed using the KAT and Catalán models. The Dynamic Solvatochromic Indicator was introduced to assess molecular resilience across different media. These insights provide valuable guidance for rational drug design, formulation strategies, and solvent selection in drug delivery systems. Experimental Materials Pure samples of benzodiazepines, namely Clonazepam and Chlordiazepoxide (listed in Table 1), were procured from ALEXIS Biochemicals (USA) with a stated purity of 99% and were used as received without further purification. These pharmaceutical–grade compounds, sourced from internationally certified suppliers, ensured consistent quality for the subsequent photophysical and spectroscopic analyses. All solvents were obtained from Merck (Germany) as spectroscopic-grade reagents with a stated purity greater than 99%. The quality of these solvents was guaranteed by the manufacturer and verified by recording baseline UV–Vis spectra before sample preparation to ensure the absence of interfering impurities. Refractive index measurements were also performed using a high-precision refractometer capable of measuring up to six decimal places, and the measured values were cross-checked against standard reference values and manufacturer data. This additional verification step provided strong confirmation of solvent purity and consistency, particularly in detecting minor discrepancies that could influence spectroscopic accuracy. Solvent polarity parameters are provided in Table 226,40. Table 1Drugs, molecular structure and IUPAC names. Drugs, molecular structure and IUPAC names. Table 2Spectroscopic Polarity parameters, physical properties and Polarity functions of employed solvents24,38.Solventε n α β π* f (ε, n) f (ε, n) +2 (g, n) 1,4–Dioxane2.221.420.000.370.490.000.440.70.0440.617Diethyl ether4.341.350.000.470.240.000.560.690.3790.855Chlorobenzene5.621.520.000.070.680.000.180.820.3921.0981–Decanol8.001.440.700.850.450.260.910.770.5531.1451–Heptanol11.301.420.640.960.390.300.910.80.6521.2271–Hexanol13.001.420.670.940.40.320.880.810.6861.2541–Butanol17.501.400.840.840.470.340.810.840.7501.2932–Propanol19.901.380.760.840.480.280.830.850.7791.292Acetone21.011.360.080.480.620.000.470.880.7921.281Ethanol24.301.360.860.750.540.400.660.850.8121.303Methanol33.701.330.980.660.600.610.550.860.8571.306Ethylene glycol37.001.430.900.520.920.720.530.930.8361.422DMF39.251.430.000.690.880.030.610.950.8421.425DMSO47.241.480.000.761.000.070.651.000.8411.489 Spectroscopic Polarity parameters, physical properties and Polarity functions of employed solvents24,38. Spectroscopic techniques UV–Visible absorption spectra were recorded using a Shimadzu UV–2450 double-beam spectrophotometer over a wavelength range of 300–800 nm, using quartz cuvettes with a 1 cm optical path length. Fluorescence spectra were obtained using a JASCO FP–6200 spectrofluorometer. All sample solutions were prepared at a concentration of 1 × 10-3 M to ensure optimal absorbance and emission profiles. Blank spectra of the corresponding pure solvents were recorded under identical instrumental and environmental conditions to ensure accurate background correction in both absorption and fluorescence measurements. These blanks were subtracted from the sample spectra to remove contributions from the solvent, cuvette, and any baseline drift. Automated baseline correction (auto–zero) was applied before each measurement using the instrument’s internal calibration protocol to further minimize background noise. For fluorescence measurements, excitation and emission slit widths, detector sensitivity, and integration times were carefully optimized and kept constant. The corrected spectra represent only the analyte response, free from background or solvent–related artifacts. Estimation of dipole moments Understanding charge redistribution within drug molecules is fundamental for predicting their interactions23–26 and, more broadly, their pharmacological behavior47–49. Dipole moments offer valuable insight into both intra-and intermolecular interactions. In this study, dipole moments were determined using solvent-dependent spectral shift analysis and second-order perturbation theory for polarizable dipoles. This methodology relies on shifts in absorption () and emission maxima in different solvents (in cm– 1)50–59 and uses two established models: the Lippert–Mataga (Eq. 1)50,51 and the Kawski–Chamma–Viallet (Eq. 2)52,53.These models relate spectral shifts to solvent polarity and allow estimation of ground–and excited–state dipole moments as follows: Linear regression of these shifts yields parameters m1​ and m2​, which are related to solvent polarity functions: Where c is the speed of light in vacuum and h is Planck’s constant. The dipole moments of the ground (​) and excited state ( were then calculated. The Onsager cavity radius ()54 was estimated from the molecular dimensions of the compounds. Additional relations used are52,53: In these relationships n,, and α represent solvent’s refractive index, dielectric constant, solute’s spherical cavity radius, and average polarizability, respectively. Under the assumption of isotropic polarizability,, the Lippert–Mataga equation provides a simplified relationship between the solvent-dependent Stokes shift and the difference between ground– and excited– states50,51: Assuming parallel alignment of dipoles in ground–and excited–states, the following expressions were used55,56: Dynamic solvatochromic indicator (DSI) The Dynamic Solvatochromic Indicator (DSI) is proposed as a complementary photophysical metric for evaluating the molecular integrity and solvatochromic responsiveness of anti–anxiety and hypnotic drugs across diverse solvent environments. This indicator integrates three key molecular parameters—Stokes shift (Δν), dipole moment change (Δµ), and solvent–accessible surface area (SAS)—providing insight into the drug’s resilience against solvent–induced perturbations. Importantly, the DSI is presented as a conceptual and complementary tool, explicitly not intended to replace conventional chemical stability assessments such as degradation kinetics or forced degradation tests. While traditional approaches (e.g., degradation kinetics and forced degradation tests) assess chemical stability under stress conditions60,61, the DSI provides a rapid, non–destructive, spectroscopic perspective on how molecular polarity and solvent interactions influence drug resilience, particularly under photoexcitation. The DSI was calculated using the following relationship: (While the individual components of the DSI equation are grounded in well–established photophysical principles, their empirical integration into a unified electrostatic-stability indicator represents a novel methodological contribution of this work). Here, Δµ (change in dipole moment upon excitation) represents the extent of intramolecular electronic redistribution, correlating with the molecule’s susceptibility to solvent–induced stabilization or destabilization. A large Δµ often implies greater reorganization energy, which can increase the likelihood of nonradiative decay or degradation pathways. Δν (Stokes shift, in cm⁻¹) indicates the energetic relaxation between the excited and ground states. A larger Stokes shift can reflect significant structural or solvation rearrangements post–excitation, often associated with enhanced vibrational coupling and energy dissipation. Expressing Δν in wavenumbers rather than wavelengths, ensures that the indicator remains independent of the absolute spectral region (UV vs. visible), allowing direct energetic comparison of the photophysical behavior of different molecules. SAS (solvent–accessible surface area) quantifies the degree of molecular exposure to the solvent environment. As described in our previous work, molecules with higher SAS values are more prone to interactions with reactive solvent species, oxygen, or other external quenchers, affecting their photochemical and chemical stability62. SAS was computed using the rolling–probe method with a probe radius of 1.4 Å, and all obtained values were converted from Å2 to m² prior to their use in the DSI equation. Molecular geometries of the investigated drugs were fully optimized using the M06–2X hybrid functional with the DGDZVP basis set. These optimized structures were then employed to evaluate SAS through the NWChem quantum–chemical package63. This procedure ensures that the calculated SAS values accurately represent molecular exposure to solvent environments relevant to their photophysical behavior. To ensure dimensional consistency and scientific clarity, the DSI expression was analyzed in terms of its fundamental units. In this formulation, Δµ is expressed in coulomb.meter (Cm), Δν is converted from cm-1 to m-1, and SAS is expressed in square meters (m²). Accordingly, the dimensional analysis yields units consistent with those of surface charge density (). Although DSI shares the same dimensional form as surface charge density, it does not represent an actual charge distribution but rather a derived electrostatic descriptor obtained from measurable photophysical parameters (Δµ, Δν, SAS). Hence, its dimensional analogy provides a useful physical interpretation that bridges molecular electrostatics and photophysical stability. Numerically, DSI corresponds to an effective electrostatic surface charge density of a molecule (C/m2), enabling direct comparison with typical charge densities found in biological systems, which are inherently variable depending on pH, ionic strength, and molecular composition. For instance, the inner leaflet of cell membranes carries strong negative patches with effective surface charge densities ranging from − 0.01 to – 0.1 Cm-2, while polar head groups of phospholipids can exhibit even higher local negative densities. Proteins display positively charged patches, such as histones binding to DNA, with surface charge densities around + 0.05 to + 0.2 Cm-2 or higher, while negatively charged regions, such as those on albumin or active enzyme sites, can reach similar magnitudes64. It is also important to note that having the same dimensionality does not imply identical physical meaning. Unlike the macroscopic definition of σ = Q/A, which quantifies real charge accumulation on extended surfaces, the DSI operates at the molecular scale and is constructed from quantum–chemical observables. Therefore, it serves as a conceptual and quantitative bridge between experimental spectroscopy and molecular stability, rather than a direct measure of electric charge. Comparing calculated DSI values for drug molecules with these biological charge densities provides insight into their electrostatic sensitivity: higher DSI values, comparable to or exceeding these biological charges, suggest that the drug is highly responsive to local electrostatic fields, which may significantly influence membrane permeability and binding to charged protein sites. Conversely, lower DSI values indicate that the drug’s behavior is dominated by non–electrostatic interactions (e.g., van der Waals forces or hydrophobic effects), making it less affected by the electrostatic heterogeneity of biological environments. Overall, DSI serves as a molecular–level predictor linking computational electrostatic data to biological relevance, helping assess drug stability and potential interactions within cells and protein environments. Results and discussion Spectral properties Clonazepam and Chlordiazepoxide exhibit distinct solvent–dependent photophysical behaviors due to differences in their functional groups, particularly the carbonyl and methylamino moieties attached to their benzodiazepine cores. Their chemical structures and IUPAC names are shown in Table 1 for reference. To investigate this, their absorption and fluorescence spectra were recorded in fourteen solvents with varying polarity. The resulting spectral data are summarized in Table 3. As shown in Fig. 1, both compounds display complex absorption and emission profiles, with no consistent trends in spectral shifts across different solvents. This irregularity reflects the combined influence of general solvent polarity and specific solute-solvent interactions. The marked red shift of Clonazepam’s absorption in methanol (347 nm) can be attributed to specific hydrogen bonding between the solvent and electron–withdrawing groups such as carbonyl and nitro moieties, which stabilizes the ground state and possibly shifts the tautomeric equilibrium. Table 3Absorption and fluorescence spectral data of benzodiazepines in various solvents.Solventλmax(Abs) (Cm− 1) (nm)λmax(Fluo) (Cm− 1) (nm)(Cm− 1)(f)(Cm− 1)Clonazepam 1,4-Dioxane(30864) 324(26385) 3794478.9757249.42 Diethyl ether(31948) 313(27322) 3664626.4859271.29 Chlorobenzene(32051) 312(26041) 3846009.6258092.95 1–Decanol(32051) 312(27548) 3634503.0759599.49 1–Heptanol(31545) 317(28328) 3533217.1359874.35 1–Hexanol(31250) 320(27624) 3623625.6958874.31 1–Butanol(31796) 314.5(25773) 3886023.3157569.70 2–Propanol(32258) 310(26809) 3735448.4159067.72 Acetone(32000) 312.5(25062) 3996937.3457062.66 Ethanol(31055) 322(25000) 4006055.9056055.90 Methanol(28818) 347(25316) 3953501.9954134.90 Ethylene glycol(31746) 315(25316) 3956429.5857062.49 DMF(31055) 322(26109) 3834946.2457165.56 DMSO(30769) 325(26595) 3764173.4957364.98Chlordiazepoxide 1,4-Dioxane(29940) 334(24814) 4035126.2254754.02 Diethyl ether(30769) 325(24630) 4066138.6955399.77 Chlorobenzene(30864) 324(24691) 4056172.8455555.56 1–Decanol(31446) 318(22883) 4378563.2554329.84 1–Heptanol(31250) 320(22321) 4488928.5753571.43 1–Hexanol(30864) 324(22522) 4448341.6853368.72 1–Butanol(31746) 315(22026) 4549719.6053772.46 2–Propanol(31055) 322(21929) 4569126.0852985.73 Acetone(30864) 324(24752) 4046111.7255616.67 Ethanol(31545) 314(22026) 4549519.3153572.17 Methanol(31250) 320(20576) 48610673.8751826.13 Ethylene glycol(31055) 322(22271) 4498784.1953327.62 DMF(29761) 336(24814) 4034948.0154575.80 DMSO(31055) 322(24691) 4056364.5455747.26 Absorption and fluorescence spectral data of benzodiazepines in various solvents. Normalized absorption and fluorescence spectra of Clonazepam (a, b) and Chlordiazepoxide (c, d) in various solvents. To further analyze polarity effects, Lippert–Mataga plots59 were constructed by correlating Stokes shift values (in cm-1) with the orientation polarizability of each solvent. According to the Lippert–Mataga theory, a linear relationship between Stokes shift and orientation polarizability is expected when solvation is dominated by nonspecific dipolar interactions. Therefore, the observed deviations from linearity indicate additional specific interactions, particularly hydrogen bonding, between solvent molecules and functional groups in the excited state. As illustrated in Fig. 2, the nonlinear nature of the plots suggests that both nonspecific dipolar interactions and specific hydrogen bonding govern the photophysical behavior of the compounds. In solvents with dielectric constants ε > 8, Clonazepam exhibited steeper slopes, indicating a greater degree of excited-state rearrangement. This corresponds to enhanced dipole moment change and intramolecular electronic redistribution upon excitation, arising from both nonspecific solvation effects and specific interactions such as hydrogen bonding that stabilize the excited state. In contrast, the low Stokes shift observed in solvents with ε < 8 suggests limited excited-state reorganization, likely due to the low polarity and reduced ability of the solvent environment to stabilize dipolar excited states via dielectric or dipole–dipole interactions. Further analysis of the absorption and emission maxima with individual polarity parameters showed weak and inconsistent correlations, highlighting the limitations of single-parameter models in capturing the full complexity of solvation effects. To address this, a multiparametric approach was employed by applying both Kamlet–Abboud–Taft (KAT) and Catalán models. Plot of Stokes’ shift (cm− 1) versus solvent orientation polarizability parameter: (a) Clonazepam and (b) Chlordiazepoxide. The KAT model (Eq. 13) describes solvent effects using three empirical polarity parameters: dipolarity/polarizability (π*)39, hydrogen-bond acceptor ability (β)40, and hydrogen–bond donor ability (α)41. These parameters quantify the general and specific interactions between solvent and solute. The Catalán model (Eq. 14), a refinement of the solvatochromic approach includes polarity/polarizability (SPP), solvent basicity (SB), and solvent acidity (SA)40. In both models, the regression coefficients (a, b, s) indicate the relative contribution of each solvent parameter to the observed spectral shifts. As shown in Tables 4 and 5, solvent–induced changes in absorption and fluorescence behavior vary significantly between the two compounds. Table 4Regression fits to Kamlet–Abboud–Taft and Catalán solvatochromic parameters for absorbance, fluorescence and stokes’ shift of benzodiazepines.Benzodiazepine R 2 Kamlet–Abboud–Taft Clonazepam Absorbance33.143(± 0.363)0.723(± 0.249)– 1.453(± 0.385)– 1.208(± 0.341)0.81 Fluorescence24.103(± 0.765)– 3.863(± 0.647)8.843(± 1.275)– 4.443(± 0.748)0.90 Stokes’ shift14.505(± 2.319)7.680(± 0.116)– 13.100(± 2.287)– 8.826(± 2.449)0.95 ChlordiazepoxideAbsorbance31.824(± 0.612)1.398(± 0.337)– 1.132(± 0.713)– 1.376(± 0.517)0.81 Fluorescence23.698(± 1.002)– 4.406(± 0.636)1.518(± 0.199)1.061(± 1.182)0.95 Stokes’ shift7.294(± 1.319)5.081(± 0.864)– 1.432(± 1.503)– 1.841(± 1.447)0.94 Catalán Clonazepam Absorbance36.031(± 2.372)3.077(± 3.064)– 3.320(± 3.240)– 3.195(± 1.747)0.81 Fluorescence25.751(± 2.405)– 2.065(± 1.146)5.666(± 1.280)– 3.213(± 2.517)0.79 Stokes’ shift18.740(± 2.895)0.740(± 0.375)– 10.175(± 1.148)– 8.006(± 2.241)0.99 Chlordiazepoxide Absorbance30.650(± 1.692)2.674(± 0.730)1.873(± 0.855)– 2.156(± 1.929)0.92 Fluorescence24.660(± 2.429)– 5.142(± 0.932)– 2.352 (± 1.140)1.572(± 2.759)0.85 Stokes’ shift7.040(± 2.739)6.330(± 1.194)2.336(± 1.301)– 2.734(± 3.087)0.81 Regression fits to Kamlet–Abboud–Taft and Catalán solvatochromic parameters for absorbance, fluorescence and stokes’ shift of benzodiazepines. Table 5Percentage contribution of Kamlet–Abboud–Taft and Catalán solvatochromic parameters for absorbance, fluorescence and stokes’ shift of benzodiazepines.BenzodiazepinePα(%)Pβ(%)Pπ*(%)Kamlet–Abboud–Taft Clonazepam Absorbance214336 Fluorescence235225 Stokes’ shift264430 Chlordiazepoxide Absorbance362935 Fluorescence632215 Stokes’ shift611722 Catalán Clonazepam Absorbance323533 Fluorescence195229 Stokes’ shift45442 Chlordiazepoxide Absorbance402832 Fluorescence572617 Stokes’ shift562024 Percentage contribution of Kamlet–Abboud–Taft and Catalán solvatochromic parameters for absorbance, fluorescence and stokes’ shift of benzodiazepines. To interpret these coefficients in the context of ground-and excited-state stability, it is important to consider the fundamental nature of the spectroscopic processes involved. Absorption occurs on a very short timescale and primarily reflects the properties of the ground state. Thus, positive regression coefficients in Eqs. (13) or (14) imply that increasing the corresponding solvent parameter raises the energy of the excited state relative to the ground state, thereby stabilizing the ground state. Fluorescence, by contrast, occurs after solvent relaxation, and reflects the behavior of the excited state. In this context, negative coefficients indicate that higher values of a solvent parameter lower the energy of the excited state, thus stabilizing it65. For Clonazepam, absorption shifts are predominantly influenced by β and π* (and correspondingly SB and SPP in the Catalán model) with negative coefficients, indicating that solvents with high hydrogen–bond acceptor ability and polarizability tend to destabilize the ground state. The sensitivity to α (and SA) is minimal, suggesting a limited role of hydrogen-bond donating ability in stabilizing the ground state. In contrast, Chlordiazepoxide absorption is more strongly affected by α and π* (and correspondingly SA and SPP), consistent with intramolecular hydrogen bonding that restricts interactions with solvent acceptors. Fluorescence behavior reveals a more complex pattern: in Clonazepam, emission is primarily influenced by β and π* (SB and SPP), whereas in Chlordiazepoxide, both α and β (SA and SB) play major roles. In both molecules, α (SA) tends to stabilize the excited state by lowering its energy, while β and π* (SB and SPP) often exert destabilizing effects, depending on molecular context. The extent of solvent–induced molecular reorientation, as reflected in the Stokes shift, is strongly correlated with the hydrogen bonding capacity of the solvent. In general, hydrogen bond donor ability (α) enhances excited–state reorientation, while acceptor ability (β) tends to reduce it. These results highlight that excited-state dynamics in benzodiazepine derivatives are governed by a delicate balance of solvent dipolarity and hydrogen bonding interactions. Regarding the regression quality (R2), both KAT and Catalán models provide good fits for solvent effects. However, the KAT shows notably better performance in predicting fluorescence and Stokes shift changes for Clonazepam, indicating its higher accuracy in accounting for hydrogen–bonding parameters and describing the solvatochromic behavior of these drugs. To further validate the applicability of the KAT and Catalán solvatochromic models, plots of the calculated versus experimentally observed absorption and fluorescence peak frequencies were constructed for Clonazepam and Chlordiazepoxide (Fig. 3). The correlation coefficients (R²) ranged from 0.80 to 0.93, indicating a satisfactory agreement between the calculated and measured values. These results confirm that both solvatochromic models reliably describe the solvent-dependent spectral behavior of the studied compounds. The plots of calculated and observed (a, b) absorption and (c, d) fluorescence peak frequencies of Clonazepam, and (e, f) absorption and (g, h) fluorescence peak frequencies of Chlordiazepoxide in solvents using Kamlet–Abboud–Taft and Catalán models, respectively. Dipole moment and solvent–accessible surface (SAS) analysis The dipole moments and solvent–accessible surface areas (SAS) of Clonazepam and Chlordiazepoxide were investigated to better understand their electronic distribution and solvent interaction profiles. Ground–state (µg) and excited–state (µe) dipole moments were estimated using solvatochromic methods based on the Lippert–Mataga formalism (Eqs. 9 and 10), with the corresponding polarity functions and linear fits shown in Fig. 4. The calculated values are summarized in Table 6. The variation of with f(ε,n) (▲) and variation of with f(ε,n) + 2 g(n)()for (a) Clonazepam (b) Chlordiazepoxide to the Lippert–Mataga equation. Table 6Dipole moments, cavity radius and correlation factor(r) of benzodiazepines.BenzodiazepineRadius()µg(D)µe(D) R 2 Clonazepam Lippert–Mataga3.22.344.490.75Chlordiazepoxide Lippert–Mataga3.84.285.960.87 Dipole moments, cavity radius and correlation factor(r) of benzodiazepines. Chlordiazepoxide exhibited higher absolute dipole moments in both states (4.28 D and 5.96 D for ground and excited states, respectively) compared to Clonazepam (2.34 D and 4.49 D). This difference is attributed to Chlordiazepoxide’s lower symmetry and the presence of electron-withdrawing and polar functionalities, particularly the oxazepam moiety. However, Clonazepam shows a larger dipole moment change (Δµ = 2.15 D vs.1.68 D), reflecting a more pronounced intramolecular charge transfer (ICT) process upon excitation. This stronger ICT contribution, together with its relatively compact and symmetric framework, enhances stability across different solvent environments. In contrast, Chlordiazepoxide, with its asymmetric structure and polar substituents, experiences solvent–dependent electronic rearrangements that increase its polarity but may reduce structural persistence in certain environments (Supplementary information). SAS analysis (Figure.5) further supports these observations. Chlordiazepoxide exhibits a higher solvent–accessible surface area, consistent with its extended conformation and polar functional groups, enabling greater interaction with the solvent environment. Conversely, Clonazepam’s compact and symmetric geometry reduces its SAS, potentially influencing solubility and transport properties. Taken together, these findings highlight that structural asymmetry, polar substituents, and ICT all contribute to increased molecular polarity and solvent accessibility. These differences are further supported by the possible tautomeric forms of the two compounds (Figure.6). As previously discussed in a DFT–based study of benzodiazepine derivatives66, these tautomers exist and are stable, rather being more resonance structures, offering insight into their photophysical behavior and informing strategies to optimize drug design for improved pharmacokinetics and bioavailability. Evaluation of the dynamic solvatochromic indicator (DSI) The solvent–dependent stability of Clonazepam and Chlordiazepoxide was assessed using the DSI (Eq. 12), which integrates photophysical and physicochemical properties, including Stokes shift (Δν), dipole moment changes (Δµ), and solvent–accessible surface area (SAS). The resulting DSI values are summarized in Table 7. Table 7Dynamic solvatochromic indicator (DSI) of benzodiazepines.Solvent (C/m²) (C/m2)ClonazepamChlordiazepoxide1,4–Dioxane6.86 × 10⁻75.84 × 10⁻7Diethyl ether7.09 × 10⁻76.99 × 10⁻7Chlorobenzene9.21 × 10⁻77.03 × 10⁻71–Decanol6.90 × 10⁻79.76 × 10⁻71–Heptanol4.93 × 10⁻710.17 × 10⁻71–Hexanol5.55 × 10⁻79.50 × 10⁻71–Butanol9.23 × 10⁻711.07 × 10⁻72–Propanol8.35 × 10⁻710.04 × 10⁻7Acetone10.63 × 10⁻76.96 × 10⁻7Ethanol9.28 × 10⁻710.85 × 10⁻7Methanol5.36 × 10⁻712.16 × 10⁻7Ethylene glycol9.85 × 10⁻710.01 × 10⁻7DMF7.58 × 10⁻75.63 × 10⁻7DMSO6.39 × 10⁻77.25 × 10⁻7 Dynamic solvatochromic indicator (DSI) of benzodiazepines. (i)Stokes shift: Structural reorganization upon excitation: The Stokes shift (Δν) reflects the extent of structural rearrangement upon photoexcitation. Although Δν does not determine stability, it contributes to the DSI when combined with Δµ and SAS. Chlordiazepoxide shows larger Δν in polar solvents (e.g., Methanol, Ethanol and 1–Butanol), indicating stronger solvent–solute interactions and greater excited–state reorganization. Clonazepam exhibits relatively large Δν in moderately polar to hydrophobic solvents (Acetone, Chlorobenzene, and Ethylene glycol), while its Δν remains smaller in highly polar solvents such as Methanol, reflecting reduced perturbation. Stokes shift: Structural reorganization upon excitation: The Stokes shift (Δν) reflects the extent of structural rearrangement upon photoexcitation. Although Δν does not determine stability, it contributes to the DSI when combined with Δµ and SAS. Chlordiazepoxide shows larger Δν in polar solvents (e.g., Methanol, Ethanol and 1–Butanol), indicating stronger solvent–solute interactions and greater excited–state reorganization. Clonazepam exhibits relatively large Δν in moderately polar to hydrophobic solvents (Acetone, Chlorobenzene, and Ethylene glycol), while its Δν remains smaller in highly polar solvents such as Methanol, reflecting reduced perturbation. (ii)Δµ: Electronic Redistribution and Receptor Interaction Potential. Changes in dipole moment (Δµ) indicate intramolecular charge transfer (ICT) and potential receptor interactions. Clonazepam exhibits a significant Δµ, and its compact, symmetric structure promotes enhanced stability and sustained activity across diverse solvents. In contrast, Chlordiazepoxide, with its asymmetric structure and polar substituents, undergoes solvent–dependent electronic rearrangements that may reduce structural persistence. Δµ: Electronic Redistribution and Receptor Interaction Potential. Changes in dipole moment (Δµ) indicate intramolecular charge transfer (ICT) and potential receptor interactions. Clonazepam exhibits a significant Δµ, and its compact, symmetric structure promotes enhanced stability and sustained activity across diverse solvents. In contrast, Chlordiazepoxide, with its asymmetric structure and polar substituents, undergoes solvent–dependent electronic rearrangements that may reduce structural persistence. (iii) SAS: Solvent Exposure and Blood–Brain Barrier Permeability. SAS: Solvent Exposure and Blood–Brain Barrier Permeability. The SAS parameter represents the molecular surface area accessible to solvent and provides indirect information about lipophilicity and membrane permeability. Clonazepam, with a more compact and symmetric structure, shows reduced SAS and higher DSI in moderately polar and hydrophobic solvents (Acetone, Chlorobenzene and Ethylene glycol). Chlordiazepoxide, with an extended polar surface, displays higher SAS and increased DSI in polar solvents (e.g., Methanol, Ethanol, 1–Butanol), indicating stronger solvent interactions, rapid metabolism, and reduced CNS (Central Nervous System) retention. Clonazepam demonstrates greater stability and blood–brain barrier permeability in moderately polar and hydrophobic environments, favoring sustained therapeutic applications such as chronic anxiety and long–term insomnia. Chlordiazepoxide exhibits its highest stability in polar protic solvents, suitable for acute treatments requiring rapid onset but shorter duration, such as episodic anxiety. These DSI differences reflect structural variations and integrate Δν, Δµ, and SAS to quantify how solvent polarity and environment dynamically affect stability. DSI provides a practical tool for comparing molecules and solvents, aiding formulation and photostability prediction, and linking solvent effects to molecular stability and bioavailability. While chemical structure governs intrinsic stability, the indicator captures solvent–dependent effects that structural reasoning alone cannot. The indicator is not intended to replace kinetic degradation or long–term stability studies. Future work could link DSI with experimental degradation rates and computational predictions. Considering that the calculated DSI values for Clonazepam and Chlordiazepoxide are several orders of magnitude smaller than the surface charge densities of neuronal membranes and proteins, it can be inferred that these drugs exhibit low sensitivity to local electric fields. Therefore, their behavior during membrane penetration and receptor binding is predominantly governed by hydrophobic interactions and hydrogen bonding rather than electrostatic effects, which is consistent with their site of action in the lipid–rich and phospholipid environments of neurons. Low DSI values with minimal variation in most solvents indicate that Clonazepam, compared with Chlordiazepoxide, maintains consistent and stable behavior in its neuronal lipid–rich environment, ensuring reliable membrane penetration and receptor binding. Conclusion This study highlights the solvent-dependent photophysical behavior of Clonazepam and Chlordiazepoxide, revealing distinct spectral responses driven by polarity, hydrogen bonding, and intramolecular interactions. The Kamlet–Abboud–Taft (KAT) and Catalán models provided a better interpretation than single–parameter scales, especially in capturing complex solvation effects. Dipole moment and solvent–accessible surface (SAS) analyses demonstrated greater polarity and solvation for Chlordiazepoxide, while Clonazepam showed higher symmetry and compactness. The Dynamic Solvatochromic Indicator (DSI) results further revealed that Clonazepam exhibits greater photophysical resilience in hydrophobic media, indicating suitability for sustained therapeutic use, whereas Chlordiazepoxide shows enhanced responsiveness in polar solvents, consistent with its rapid–onset pharmacological profile. These findings emphasize the importance of combining spectral, dipolar, and solvation analyses to predict drug stability and performance in biological environments, offering useful insights for formulation development and targeted drug design. SAS for the optimized benzodiazepine molecules: (a) Clonazepam (b) Chlordiazepoxide. Possible tautomeric forms of benzodiazepines (a) Clonazepam (b) Chlordiazepoxide. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors thank the University of Tabriz for providing research facilities. Author contributions Roshanak Kian—Studied, analyzed, and evaluated the data and wrote and edited the manuscriptMohammad Sadegh Zakerhamidi—supervision—studied, analyzed, and evaluated the data and wrote and edited the manuscriptZeynab Ara Meragin—Data collection. Data availability All data generated or analyzed during this study are included in this published article. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Roshanak Kian, Email: Roshanak_kian@tabrizu.ac.ir. Mohammad Sadegh Zakerhamidi, Email: Zakerhamidi@tabrizu.ac.ir. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analyzed during this study are included in this published article.